Opinion|Videos|July 2, 2024
Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- A subcutaneous form of ocrelizumab may come to market later this year. How will you incorporate this into your treatment algorithms?
- Will payers evaluate coverage decisions for this therapy differently than the intravenous form?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers
2
Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies
3
Ebola Cases Top 1700 as Unpaid Health Workers Strike
4
Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B
5